ArticleEMBO molecular medicine2020
A combination of two human monoclonal antibodies cures symptomatic rabies.
Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Peripheral human mAb therapy yields modulation of neuroinflammation and long-term functional recovery from lyssavirus infection.Emerging microbes & infections · 2026Article
- Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy.Pharmaceutics · 2026Review
- Structural overview of lyssavirus glycoproteins, antibodies, and receptors.Journal of virology · 2026Review
- Rabies lyssavirus phosphoprotein possesses RNA duplex-unwinding activities.Molecular therapy. Nucleic acids · 2026Article
- A SynB1-conjugated antibody cocktail crosses the blood-brain barrier to produce a therapeutic effect on rabies.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles.Emerging microbes & infections · 2025Article
- Article
- The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025.China CDC weekly · 2025Article
- Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model - China, 2025.China CDC weekly · 2025Article
- Article
- Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.Cell host & microbe · 2025Article
- Immunological findings of West Caucasian bat virus in an accidental host.Journal of virology · 2025Article
- Two Decades of Human Rabies in Brazil: Epidemiological Trends, Emerging Risks and Treatment Challenges.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Nanobodies as antivirals against rabies in experimentally infected mice.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Review
- Resveratrol inhibits rabies virus infection in N2a cells by activating the SIRT1/Nrf2/HO-1 pathway.Heliyon · 2024Article
- Monoclonal antibody applications in travel medicine.Tropical diseases, travel medicine and vaccines · 2024Review
- mAb therapy controls CNS-resident lyssavirus infection via a CD4 T cell-dependent mechanism.EMBO molecular medicine · 2023Article
- Article
- Characterisation of a Live-Attenuated Rabies Virus Expressing a Secreted scFv for the Treatment of Rabies.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
Rabies is a neglected disease caused by a neurotropic Lyssavirus, transmitted to humans predominantly by the bite of infected dogs. Rabies is preventable with vaccines or proper post-exposure prophylaxis (PEP), but it still causes about 60,000 deaths every year. No cure exists after the onset of clinical signs, and the case-fatality rate approaches 100% even with advanced supportive care. Here, we report that a combination of two potent neutralizing human monoclonal antibodies directed against the viral envelope glycoprotein cures symptomatic rabid mice. Treatment efficacy requires the concomitant administration of antibodies in the periphery and in the central nervous system through intracerebroventricular infusion. After such treatment, recovered mice presented good clinical condition, viral loads were undetectable, and the brain inflammatory profile was almost normal. Our findings provide the unprecedented proof of concept of an antibody-based therapeutic approach for symptomatic rabies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.